filociclovir
Small moleculeexperimental
Filociclovir is an antiviral drug which was developed for the treatment of cytomegalovirus infection and also shows some activity against other double-stranded DNA viruses. It has reached Phase II human clinical trials. — Wikipedia
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2011 (NCT01433835)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Phosphotransferase pUL97INHIBITOR
UL97 inhibitor
- DNA polymeraseINHIBITOR
UL54 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Nc1nc2c(ncn2/C=C2/CC2(CO)CO)c(=O)[nH]1- Mol. weight
- 263.26 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaFilociclovir ↗
- ChEMBLCHEMBL265948 ↗
Also known as
- 9-((2,2-bis(hydroxymethyl)cyclopropylidene)methyl)guanine
- cyclopropavir
- cyclopropavir
- cyclopropavir
- filociclovir
- filociclovir
- filociclovir
- mbx400
- mbx400
- mbx-400
- mbx-400
- mbx-400
- (z)-9-((2,2-bis-(hydroxymethyl)cyclopropylidene)methyl)guanine
- zdm-i-62
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02454699 | Phase 1 | Nov 10, 2015 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT01433835 | Phase 1 | Sep 1, 2011 | Frontage Laboratories, Inc., Microbiotix, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Frontage Laboratories, Inc. | For profit | 1 | 0 | 1 | 2011 |
| Microbiotix, Inc. | For profit | 1 | 1 | 1 | 2011 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 2015 |
3 organizations
Page 1 / 1